Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers

Journal of the American College of Cardiology

Volumn 57, Issue 1, 2011, Pages 63-69

  Arsenault, Benoit J ^a   Barter, Philip ^b   Demicco, David A ^c   Bao, Weihang ^c   Preston, Gregory M ^c   Larosa, John C ^d   Grundy, Scott M ^e   Deedwania, Prakash ^f   Greten, Heiner ^g   Wenger, Nanette K ^h   Shepherd, James ⁱ   Waters, David D ^j   Kastelein, John J P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b HEART RESEARCH INSTITUTE   (Australia)

^c PFIZER INC   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j SAN FRANCISCO GENERAL HOSPITAL   (United States)

more..

Author keywords

biomarkers; coronary heart disease; inflammation; lipids; oxidative stress; statins

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CYSTATIN C; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NEOPTERIN; OSTEOPONTIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET RESTRICTION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART ARREST; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STROKE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 78650526061     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.06.052     Document Type: Article

References (25)

1. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
2. R.R. Packard, and P. Libby Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction Clin Chem 54 2008 24 38
3. S.M. Boekholdt, C.E. Hack, and M.S. Sandhu C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 19932003 Atherosclerosis 187 2006 415 422
4. P.M. Ridker, C.P. Cannon, and D. Morrow C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
5. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
6. P.M. Ridker, N.P. Paynter, N. Rifai, J.M. Gaziano, and N.R. Cook C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men Circulation 118 2008 2243 2251 4p following 2251
7. J. Danesh, J.G. Wheeler, and G.M. Hirschfield C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease N Engl J Med 350 2004 1387 1397
8. N. Sarwar, N. Sattar, V. Gudnason, and J. Danesh Circulating concentrations of insulin markers and coronary heart disease: a quantitative review of 19 Western prospective studies Eur Heart J 28 2007 2491 2497
9. M. Helfand, D.I. Buckley, and M. Freeman Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force Ann Intern Med 151 2009 496 507
10. J.C. LaRosa, S.M. Grundy, and D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
11. B. Zethelius, L. Berglund, and J. Sundstrom Use of multiple biomarkers to improve the prediction of death from cardiovascular causes N Engl J Med 358 2008 2107 2116
12. J.S. Rana, M. Ct, and J.P. Desprs Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study Heart 95 2009 1682 1687
13. W. Koenig, C.Y. Vossen, Z. Mallat, H. Brenner, J. Benessiano, and D. Rothenbacher Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease Eur Heart J 30 2009 2742 2748
14. U. Singh, S. Devaraj, I. Jialal, and D. Siegel Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome Am J Cardiol 102 2008 321 325
15. J. Bonnet, R. McPherson, and A. Tedgui Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study Clin Ther 30 2008 2298 2313
16. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 2004 1071 1080
17. M.C. Meuwese, M.D. Trip, S. van Wissen, J.N. van Miert, J.J. Kastelein, and E.S. Stroes Myeloperoxidase levels are not associated with carotid atherosclerosis progression in patients with familial hypercholesterolemia Atherosclerosis 197 2008 916 921
18. D.A. Morrow, J.A. de Lemos, and M.S. Sabatine Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial Circulation 114 2006 281 288
19. B.J. Arsenault, A. Cartier, and M. Ct Body composition, cardiorespiratory fitness, and low-grade inflammation in middle-aged men and women Am J Cardiol 104 2009 240 246
20. D.J. Rader Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus Am J Med 120 2007 S12 S18
21. L. Fontana, J.C. Eagon, M.E. Trujillo, P.E. Scherer, and S. Klein Visceral fat adipokine secretion is associated with systemic inflammation in obese humans Diabetes 56 2007 1010 1013
22. A.H. Berg, and P.E. Scherer Adipose tissue, inflammation, and cardiovascular disease Circ Res 96 2005 939 949
23. P.M. Ridker Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT) J Thromb Haemost 7 Suppl 1 2009 332 339
24. V. Essebag, J. Genest Jr., S. Suissa, and L. Pilote The nested case-control study in cardiology Am Heart J 146 2003 581 590
25. T. Mueller, A. Gegenhuber, W. Poelz, and M. Haltmayer Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease Clin Chem 49 2003 976 979